PsoProtectMe is a new initiative by PsoProtect for psoriasis patients to self-report their COVID-19 experience.
The Irish Skin Foundation is delighted to be a partner of PsoProtect, an international registry for health care providers to report outcomes of COVID-19 in individuals with psoriasis. PsoProtect has released data from over 100 cases reported by clinicians globally, including from Italy, Spain, UK, Malaysia, France, Canada, Belgium, Ireland, Sweden, Portugal and Argentina.
PsoProtect have now announced a further initiative for patients with psoriasis to self-report their experiences during the current COVID-19 pandemic, called PsoProtectMe.
PsoProtectMe seeks to understand the experiences, symptoms and health behaviours of individuals with psoriasis during the pandemic. Anyone with psoriasis from all over the world, whether or not they have had COVID-19, can take part in a simple online survey which takes between 5-10 minutes to complete.
The survey asks about symptoms, psoriasis treatments and any underlying health conditions people with psoriasis may have. If the person has had COVID-19, the survey will explore how this has affected them and their psoriasis.
PsoProtectMe along with PsoProtect, will help to determine how factors such as immunomodulator therapies and comorbidities impact outcomes of COVID-19 in psoriasis. This information will inform clinicians when assessing risk and treating patients with psoriasis.
The information will help to understand how the pandemic is affecting people with psoriasis, and whether the treatments used for psoriasis increase (or decrease) the risk of severe COVID-19 infection and help healthcare professionals make important decisions about the clinical care of people with psoriasis during the pandemic.
For more information visit the PsoProtect website.